The world is entering an era of untreatable infections. Without urgent action, once easily curable infections could become global health crises.
Summit approach to tackling this problem is to use its Discuva Platform to develop new mechanism antibiotics.
Antibiotic resistance: A Global Healthcare Issue
Antibiotic resistance is one of the world’s most pressing public health problems. Bacteria that were once easily treatable can become dangerous infections if they develop resistance to antibiotics. The incidence of infections due to resistance organisms is on the rise with the 2016 Review on Antimicrobial Resistance estimating that 700,000 patients die annually from antibiotic resistant infections; this figure has been projected to rise to 10 million by 2050 if no action is taken.
About Our Discuva Platform
Our proprietary Discuva Platform facilitates the discovery and development of new mechanism antibiotics. This platform combines transposon technology with bioinformatics to create a powerful tool to identify new antibacterial drug targets, elucidate antibiotic mechanisms of action and optimise against bacterial resistance to generate new antibiotic drug candidates.
The Discuva Platform is utilising proprietary libraries of multiple pathogens associated with antibiotic resistance. These provide excellent coverage against the ESKAPE pathogens, a leading cause of multi-drug resistance and hospital acquired infections throughout the world, and pathogens listed as urgent or serious threats by the US Centers for Disease Control or the World Health Organization.
We recently announced the identification of two novel targets to kill Neisseria gonorrhoeae bacteria and are actively working on other bacterial targets.